Police raid striking doctors' homes, offices, after deadline passes on return-to-work order
Yoon touts improved Japan ties on Independence Movement Day as gateway to 'new world'
S. Korea, US voice 'deep concern' over NK's definition of S. Korea as 'hostile' country
S.Coups of Seventeen gets military exemption due to knee injury
Korean stocks benefit from Zuckerberg's Seoul visit
Vote on bill to probe first lady lays bare Democratic Party split
Address by President Yoon Suk Yeol on the 105th March 1st Independence Movement Day
Cooperation among N. Korea, Russia, China, Iran raises possibility of 'simultaneous conflicts': US general
[Editorial] A country for children
Man jailed for fraud after faking lottery forecast program
Hyundai Bioscience, US NIH to co-develop broad-spectrum antiviral drugBy Yonhap
Published : Aug. 13, 2023 - 20:11
Hyundai Bioscience said Sunday it will develop a broad-spectrum antiviral drug with the US National Institutes of Health, a federal agency for conducting and supporting medical research.
Hyundai Bioscience USA, a wholly owned subsidiary of Hyundai Bioscience, signed a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) under the NIH.
Under the contract, Hyundai Bioscience USA will provide Xafty (CP-COV03), a candidate for COVID-19 antivirals, to the NIAID, which will conduct various non-clinical experiments with it.
The partnership between Hyundai Bioscience USA and the NIAID is part of the Antiviral Program for Pandemics that the US government has run since the COVID-19 pandemic.
The APP is aimed at developing "safe and effective antivirals to combat" the virus that caused COVID-19, as well as building "sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential."
Hyundai Bioscience said the two parties will conduct experiments to see if Xafty can treat 10 viruses, including MERS and RSV, and continue working together through the phase 2 clinical study.
In June, Hyundai Bioscience filed the results of the clinical study of Xafty with the Korea Disease Control and Prevention Agency for emergency use authorization on COVID-19.
It said the antiviral has shown high efficacy even in the high-risk group for COVID-19. (Yonhap)
Opposition leader retains ticket to his constituency
Car camping: How solo female campers enjoy outdoors
Tensions loom as doctors plan mass rally in deepening clash over med school quota